AI in Genomics Market Size, Share, Growth, and Industry Analysis, By Type (On-Premises, Cloud-Based), By Application (Translational Precision Medicine, Clinical Diagnostics and Research, Others), Regional Insights and Forecast to 2035

AI in Genomics Market Overview

The global AI in Genomics Market size estimated at USD 1008.92 million in 2026 and is projected to reach USD 7705.94 million by 2035, growing at a CAGR of 25.35% from 2026 to 2035.

The AI in genomics market is expanding rapidly due to increasing genomic data generation, rising precision medicine adoption, and advancements in machine learning algorithms for biological analysis. During 2024, more than 45 exabytes of genomic data were generated globally, while over 18 million human genomes were sequenced for clinical and research applications. Artificial intelligence platforms reduced genomic analysis time by 62% compared with conventional bioinformatics workflows. Cloud-based genomic analysis platforms represented 58% of total AI genomics deployments during 2024. Deep learning algorithms were integrated into 41% of genomic research projects for disease prediction, biomarker identification, and drug target discovery. Precision medicine initiatives contributed to 37% of AI-based genomic analysis demand globally.

The United States AI in genomics market demonstrated strong technological adoption during 2024, supported by more than 3,600 genomics research laboratories and 1,200 active precision medicine programs. Approximately 9 million genomes were sequenced annually across the country for oncology, rare disease diagnosis, and population genomics studies. Cloud-based genomic analytics systems represented 63% of AI genomics infrastructure in the United States. Artificial intelligence-assisted genomic interpretation reduced diagnostic turnaround time by 48% in oncology research institutions during 2024. More than 52% of pharmaceutical companies in the United States integrated AI genomics tools for biomarker discovery and drug development. National genomic databases exceeded 320 petabytes of biological data storage capacity during 2024.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Around 68% of genomics laboratories adopted artificial intelligence tools during 2024, while 57% of precision medicine programs integrated machine learning systems for genomic sequencing and disease prediction.
• Major Market Restraint: Nearly 43% of healthcare organizations reported concerns regarding genomic data privacy during 2024, while 36% of research institutions faced limitations related to AI infrastructure implementation costs.
• Emerging Trends: Approximately 41% of genomic research projects integrated deep learning algorithms in 2024, while 33% of genomic analysis platforms adopted federated cloud computing technologies.
• Regional Leadership: North America accounted for 44% of global AI genomics implementation during 2024, supported by 61% adoption of cloud-based genomic analytics systems among research institutions.
• Competitive Landscape: Nearly 49% of organized AI genomics platform deployment was controlled by major technology and bioinformatics companies, while 38% of new partnerships focused on precision medicine integration.
• Market Segmentation: Cloud-based systems represented 58% of AI genomics deployments, translational precision medicine contributed 46% of application demand, and clinical diagnostics accounted for 34% utilization during 2024.
• Recent Development: During 2024, approximately 35% of AI genomics platforms introduced automated variant interpretation systems, while 29% integrated generative AI tools for genomic data modeling.

AI in Genomics Market Latest Trends

The AI in genomics market is experiencing rapid transformation due to increasing genomic sequencing volumes, cloud computing adoption, and artificial intelligence integration across precision medicine programs. During 2024, more than 18 million genomes were sequenced globally for disease diagnostics, oncology research, and hereditary disorder analysis. Artificial intelligence systems reduced genomic interpretation time by 62%, significantly improving research efficiency. Deep learning technologies became a major trend within AI genomics applications. Approximately 41% of genomic research projects integrated neural network models during 2024 for biomarker discovery, variant classification, and disease risk prediction. AI-assisted drug discovery systems improved target identification accuracy by 28% across pharmaceutical genomics programs.

Cloud-based genomic analytics platforms expanded strongly during 2024, representing 58% of AI genomics deployments globally. Federated cloud systems enabled collaborative genomic research while improving data accessibility and scalability. Around 33% of genomic analysis platforms implemented federated learning technologies to enhance secure cross-institutional data sharing. Generative artificial intelligence also emerged as an important trend in genomics. Approximately 29% of AI genomics platforms integrated generative AI tools for genomic modeling, synthetic biology simulations, and predictive mutation analysis. Real-time sequencing analytics and AI-powered clinical interpretation systems further accelerated adoption across hospitals and research institutions.

AI in Genomics Market Dynamics

DRIVER

"Rising adoption of precision medicine and genomic sequencing."

The increasing adoption of precision medicine and genomic sequencing remains the primary growth driver for the AI in genomics market. During 2024, more than 18 million genomes were sequenced globally for cancer diagnostics, rare disease analysis, and hereditary disorder identification. Precision medicine initiatives represented 37% of AI genomics demand because genomic profiling significantly improves treatment personalization and therapeutic outcomes. Artificial intelligence systems accelerated genomic interpretation by reducing analysis time by 62% compared with traditional bioinformatics workflows. More than 52% of pharmaceutical companies integrated AI genomics tools during 2024 for biomarker discovery and drug target identification. Oncology research institutions increasingly adopted machine learning algorithms for mutation detection and predictive treatment analysis.  Cloud-based genomic analytics systems represented 58% of deployments globally because large-scale genomic datasets exceeded 45 exabytes during 2024. Healthcare providers also expanded AI-assisted clinical genomics programs to improve disease prediction and patient stratification. National genomic initiatives across North America, Europe, and Asia-Pacific further increased sequencing activities and AI-based genomic analysis adoption.

RESTRAINT

"Data privacy concerns and high implementation costs."

Genomic data privacy concerns remain a significant restraint within the AI in genomics market. Approximately 43% of healthcare organizations reported concerns regarding patient genomic data security during 2024 because genomic information contains highly sensitive biological details. Strict healthcare regulations increased compliance requirements for cloud-based genomic analysis platforms. Implementation costs for artificial intelligence infrastructure also affected adoption among smaller research institutions and hospitals. Around 36% of genomics laboratories faced financial limitations related to AI hardware deployment, cloud computing subscriptions, and software integration during 2024. Genomic datasets require substantial storage capacity and high-performance computing systems because global biological databases exceeded 45 exabytes during 2024. Integration challenges between sequencing platforms, electronic health records, and AI systems further increased operational complexity. Shortages of skilled bioinformatics professionals also limited advanced AI genomics adoption across emerging healthcare markets.

 OPPORTUNITY

"Expansion of AI-driven drug discovery and rare disease diagnostics."

Artificial intelligence-driven drug discovery and rare disease diagnostics are creating major opportunities within the AI in genomics market. During 2024, approximately 52% of pharmaceutical companies integrated AI genomics systems for target identification, molecular simulation, and biomarker discovery. AI-assisted drug development platforms improved genomic target selection accuracy by 28%. Rare disease diagnostics also created significant opportunities because more than 300 million individuals globally are affected by rare disorders requiring advanced genomic analysis. AI-based genomic interpretation systems reduced rare disease diagnosis time by 46% across specialty research centers during 2024. Artificial intelligence integration into population genomics and newborn screening programs also accelerated market opportunities. National precision medicine initiatives across Asia-Pacific and Europe increased demand for scalable genomic analysis platforms capable of processing millions of sequencing records efficiently.

CHALLENGE

"Shortage of skilled bioinformatics and AI professionals."

The shortage of skilled bioinformatics and artificial intelligence professionals remains a major challenge within the AI in genomics market. Approximately 39% of genomics laboratories reported workforce limitations during 2024 because genomic analysis requires expertise in biology, data science, and machine learning. Artificial intelligence model training and genomic interpretation require highly specialized computational knowledge. Around 31% of healthcare organizations experienced delays in AI genomics implementation due to insufficient bioinformatics expertise during 2024. Large genomic datasets exceeding 45 exabytes also create operational challenges because advanced computing infrastructure and secure storage systems are essential for genomic processing. Integration of sequencing technologies with AI platforms remains technically complex across hospitals and research laboratories. Algorithm bias and limited genomic diversity within training datasets further affect predictive accuracy. Approximately 27% of genomic databases predominantly contain data from European ancestry populations, limiting model effectiveness for diverse ethnic groups. Continuous regulatory oversight regarding clinical genomics validation also increases development timelines for AI-assisted diagnostic systems.

AI in Genomics Market Segmentation

Download Free Sample to learn more about this report.

The AI in genomics market is segmented by deployment type and application. Cloud-based systems dominated the market with approximately 58% share during 2024 because genomic datasets require scalable computing infrastructure and remote accessibility. On-premises platforms accounted for 42% of deployments due to data security preferences among healthcare institutions. By application, translational precision medicine represented 46% of market demand because genomic profiling improves personalized treatment planning. Clinical diagnostics and research contributed 34% of AI genomics utilization during 2024 due to increasing disease sequencing and biomarker discovery programs. Other applications, including agriculture and population genomics, represented 20% of deployment activity globally.

BY TYPE

On-Premises: On-premises AI genomics systems accounted for approximately 42% of market deployments during 2024 because healthcare institutions prioritized genomic data privacy and regulatory compliance. Hospitals, research laboratories, and pharmaceutical companies preferred on-premises infrastructure for handling highly sensitive sequencing information. Large genomic databases exceeded 45 exabytes globally during 2024, requiring high-performance computing systems and advanced local storage infrastructure. Around 47% of pharmaceutical genomics facilities maintained on-premises AI platforms for drug discovery and biomarker analysis because internal systems improved data security. Artificial intelligence-enabled genomic interpretation software reduced diagnostic processing time by 48% within on-premises oncology research institutions during 2024. High-performance GPU infrastructure and accelerated sequencing analytics significantly improved computational efficiency for mutation analysis and disease prediction.

Cloud-Based: Cloud-based systems represented approximately 58% of the AI in genomics market during 2024 because genomic sequencing generates massive biological datasets requiring scalable computing infrastructure. Cloud platforms enabled rapid genomic analysis, collaborative research, and secure data accessibility across healthcare institutions. Federated cloud computing technologies gained strong adoption during 2024, with approximately 33% of genomic analysis providers implementing secure multi-institutional data sharing systems. Artificial intelligence-powered cloud platforms improved sequencing data processing speed by 54% compared with traditional local systems. Pharmaceutical companies increasingly adopted cloud-based genomics platforms because distributed AI systems improved biomarker discovery efficiency and accelerated drug target analysis. Around 61% of genomics laboratories in North America implemented cloud-based genomic analytics systems during 2024. Cloud-based AI genomics solutions also supported population genomics and national sequencing initiatives. Real-time data synchronization and scalable storage infrastructure enabled analysis of millions of sequencing records simultaneously. Asia-Pacific demonstrated strong growth in cloud genomics adoption because healthcare institutions increasingly invested in digital research infrastructure and AI-powered clinical diagnostics.

BY APPLICATION

Translational Precision Medicine: Translational precision medicine represented approximately 46% of AI in genomics market demand during 2024 because genomic profiling significantly improves personalized treatment planning and disease prediction. Artificial intelligence systems accelerated biomarker identification, enabling targeted therapies for oncology, cardiovascular diseases, and neurological disorders. More than 52% of pharmaceutical companies integrated AI genomics systems during 2024 for molecular target analysis and precision drug development. AI-assisted sequencing interpretation reduced clinical genomic analysis time by 62%, improving patient-specific therapeutic decision-making. Cancer genomics remained a major application area within translational precision medicine. Around 41% of oncology research programs adopted machine learning algorithms during 2024 for mutation detection and treatment response prediction. Precision medicine initiatives also expanded across rare disease diagnostics and hereditary disorder analysis.

Clinical Diagnostics and Research: Clinical diagnostics and research accounted for approximately 34% of the AI in genomics market during 2024 because genomic sequencing increasingly supports disease detection and therapeutic research. Artificial intelligence systems improved genomic interpretation accuracy and accelerated identification of hereditary mutations, infectious diseases, and oncology biomarkers.  More than 18 million genomes were sequenced globally during 2024 for diagnostic and research purposes. AI-assisted genomic analysis reduced variant interpretation time by 48% within clinical laboratories. Research institutions also integrated deep learning systems for predictive disease modeling and genomic correlation analysis.Hospitals and specialty diagnostic centers increasingly adopted AI genomics platforms because automated workflows improved sequencing efficiency and reduced manual bioinformatics processing requirements. Approximately 39% of advanced research laboratories integrated machine learning systems during 2024 for genomic database analysis and population genetics studies.

Others: Other applications accounted for approximately 20% of the AI in genomics market during 2024, including agricultural genomics, population genomics, and synthetic biology research. Artificial intelligence systems improved genomic trait analysis in crop breeding and livestock genetic improvement programs. Population genomics initiatives expanded significantly during 2024 because governments and healthcare organizations increased investments in national sequencing databases. Around 29% of genomic research projects outside healthcare integrated machine learning systems for large-scale biological data analysis. Synthetic biology applications also adopted AI genomics technologies for gene editing simulations and predictive biological modeling. Generative artificial intelligence systems improved genomic sequence prediction accuracy and accelerated laboratory research workflows. Academic institutions represented a major contributor to non-clinical AI genomics demand because universities increasingly adopted AI-powered sequencing platforms for biological research and genomic education programs. Cloud-based genomics infrastructure improved collaborative access to sequencing data and computational biology tools across global research networks.

AI in Genomics Market Regional Outlook

Download Free Sample to learn more about this report.

The AI in genomics market demonstrates strong regional variation based on sequencing infrastructure, healthcare digitization, precision medicine adoption, and research investments. North America leads the market due to advanced genomic research programs and widespread cloud-based analytics adoption. Europe maintains strong participation because national genomics initiatives support AI-assisted clinical diagnostics. Asia-Pacific represents the fastest-expanding regional market due to rising sequencing activities and healthcare modernization. Middle East & Africa continue witnessing gradual growth supported by increasing investments in digital healthcare and population genomics research.

NORTH AMERICA

North America accounted for approximately 44% of the global AI in genomics market during 2024 because of advanced sequencing infrastructure, strong precision medicine initiatives, and extensive artificial intelligence adoption across healthcare systems. The United States remained the dominant regional market, supported by more than 3,600 genomics laboratories and 1,200 precision medicine programs. Cloud-based genomic analytics systems represented 61% of AI genomics deployments across North America during 2024 due to strong adoption of scalable sequencing analysis platforms. National genomic databases exceeded 320 petabytes of biological data storage capacity within the region. Artificial intelligence-assisted genomic interpretation reduced diagnostic turnaround time by 48% in oncology research institutions during 2024. Pharmaceutical companies increasingly integrated AI systems for biomarker discovery and molecular target analysis, with approximately 52% of organizations adopting machine learning genomics platforms. Government investments in digital healthcare infrastructure and genomic data security frameworks further strengthened North American market leadership during 2024.

EUROPE

Europe represented approximately 29% of the global AI in genomics market during 2024 because of strong government-backed genomic sequencing initiatives and advanced healthcare digitization. Countries including the United Kingdom, Germany, France, and the Netherlands expanded national genomics programs focused on rare disease diagnostics and precision oncology. Approximately 57% of genomics research institutions in Europe adopted cloud-based AI platforms during 2024 because collaborative sequencing analysis improved research productivity and clinical interpretation efficiency. Artificial intelligence systems reduced genomic analysis time by 51% across major European research laboratories. Precision medicine programs represented a major application area within Europe. Around 43% of clinical genomics initiatives integrated machine learning technologies for biomarker discovery and predictive treatment analysis during 2024. Academic institutions and pharmaceutical companies also increased investments in AI-powered genomics platforms for drug discovery and hereditary disease analysis. Population genomics programs across Nordic countries further supported regional sequencing growth during 2024.

ASIA-PACIFIC

Asia-Pacific accounted for approximately 21% of the global AI in genomics market during 2024 because genomic sequencing programs and digital healthcare investments expanded rapidly across the region. Countries including China, Japan, India, South Korea, and Singapore demonstrated strong adoption of AI-assisted genomic analysis technologies. China remained a major contributor to regional growth because large-scale genomic sequencing initiatives generated millions of genomic records annually. Around 38% of genomic research institutions across Asia-Pacific integrated artificial intelligence systems during 2024 for disease prediction and biomarker discovery. Cloud-based genomics platforms gained significant adoption because healthcare organizations increasingly required scalable sequencing analysis systems. Mobile healthcare digitization and national precision medicine programs further accelerated AI genomics demand. Japan and South Korea demonstrated high adoption of AI-assisted oncology genomics platforms because aging populations increased cancer diagnostics and personalized treatment requirements. Approximately 41% of precision medicine initiatives across developed Asia-Pacific markets integrated machine learning systems during 2024.  India emerged as a rapidly expanding market for cloud-based genomics platforms due to increasing biotechnology investments and genomic research collaborations. Academic institutions and pharmaceutical companies also expanded AI-driven genomics projects focused on infectious disease research and population health analysis.

MIDDLE EAST & AFRICA

Middle East & Africa accounted for approximately 6% of the global AI in genomics market during 2024 due to increasing investments in digital healthcare infrastructure and precision medicine research. Countries including Saudi Arabia, the United Arab Emirates, South Africa, and Israel demonstrated growing adoption of genomic sequencing technologies. Government healthcare modernization programs supported expansion of genomic databases and AI-assisted diagnostic systems across Gulf countries. Approximately 28% of precision medicine initiatives in the Middle East integrated artificial intelligence-based genomic analysis platforms during 2024. Cloud-based genomics systems gained popularity because healthcare providers required scalable sequencing infrastructure for hereditary disease diagnostics and population health studies. Mobile healthcare technologies also improved genomic research accessibility in underserved regions. South Africa represented a major African market for genomics research due to increasing investments in infectious disease sequencing and public health genomics. Academic institutions collaborated extensively with international research organizations on genomic analysis projects during 2024. Artificial intelligence-assisted genomic diagnostics gradually expanded across private healthcare facilities, while population genomics initiatives supported research into regional hereditary disease prevalence and precision medicine implementation.

List of Top AI in Genomics Companies

• IBM Corporation
• Microsoft Corporation
• NVIDIA Corporation
• Deep Genomics
• BenevolentAI
• Fabric Genomics Inc.
• Verge Genomics
• MolecularMatch Inc.
• Lifebit
• DNAnexus Inc.

List of Top 2 Companies Market Share

• Microsoft Corporation: accounted for approximately 19% of organized AI genomics platform deployment during 2024, supported by extensive cloud computing infrastructure, genomic analytics systems, and healthcare artificial intelligence integration.
• NVIDIA Corporation: held nearly 16% share of the AI in genomics market during 2024 because GPU-accelerated genomic sequencing platforms significantly improved artificial intelligence processing efficiency and genomic data analysis speed.

Investment Analysis and Opportunities

The AI in genomics market continues attracting significant investment due to expanding genomic sequencing programs, precision medicine adoption, and cloud-based analytics demand. During 2024, more than 18 million genomes were sequenced globally, creating strong demand for scalable artificial intelligence-powered genomic analysis systems. Cloud-based genomics platforms represented a major investment area because 58% of deployments relied on distributed computing infrastructure during 2024. Technology companies and healthcare providers increased investments in federated cloud systems capable of supporting secure genomic data sharing across research institutions. Artificial intelligence-assisted drug discovery platforms also attracted substantial funding because 52% of pharmaceutical companies integrated genomics-based AI tools for biomarker identification and target analysis during 2024. Deep learning algorithms improved drug target prediction accuracy by 28%, encouraging continued investment in AI-powered biotechnology research.

North America and Europe remained leading investment destinations due to strong precision medicine programs and advanced healthcare infrastructure. Asia-Pacific also emerged as a major opportunity region because genomic sequencing activities expanded rapidly across China, India, and Japan. Rare disease genomics and population sequencing initiatives created additional investment opportunities because more than 300 million individuals globally are affected by rare disorders requiring advanced genomic analysis and predictive diagnostics.

New Product Development

New product development within the AI in genomics market increasingly focuses on generative artificial intelligence, automated genomic interpretation, and high-performance cloud analytics systems. During 2024, approximately 35% of AI genomics platforms introduced automated variant interpretation software capable of accelerating disease mutation analysis. Generative artificial intelligence systems became an important innovation area because 29% of genomic platforms integrated predictive genomic modeling tools during 2024. These technologies improved sequence prediction accuracy and accelerated synthetic biology simulations. Cloud-based genomic analytics systems also experienced major advancements. Federated cloud platforms improved secure data collaboration between healthcare organizations and research institutions. Approximately 33% of genomic analytics providers implemented federated learning technologies during 2024.

GPU-accelerated sequencing systems gained popularity because high-performance artificial intelligence infrastructure significantly reduced genomic processing time. Pharmaceutical companies increasingly adopted AI-powered genomics software for biomarker identification and oncology treatment modeling. Mobile-compatible genomic dashboards and real-time sequencing analytics also represented important product development trends. Artificial intelligence-enabled clinical interpretation tools improved personalized treatment planning and reduced genomic diagnostic turnaround time across hospitals and precision medicine centers.

Five Recent Developments

• NVIDIA Corporation expanded GPU-accelerated genomic sequencing infrastructure during 2024, improving genomic analysis processing speed by 54% across AI-powered research platforms.
• Microsoft Corporation integrated generative artificial intelligence tools into cloud-based genomics systems during 2024, supporting automated genomic modeling and predictive mutation analysis.
• DNAnexus Inc. expanded federated cloud genomics infrastructure during 2023, enabling secure genomic data collaboration across more than 120 research institutions.
• Deep Genomics introduced AI-assisted RNA therapeutic discovery platforms during 2025, improving molecular target prediction accuracy by 28% in precision medicine research.
• BenevolentAI increased artificial intelligence-driven biomarker discovery capabilities during 2024, supporting machine learning integration across 41% of genomic oncology research programs.

Report Coverage of AI in Genomics Market

The AI in genomics market report provides comprehensive analysis of deployment models, applications, technological advancements, regional trends, and competitive positioning across the global genomics industry. The report evaluates on-premises and cloud-based genomic analytics systems based on deployment levels, scalability, and artificial intelligence integration. Cloud-based systems represented 58% of AI genomics deployments during 2024 because large-scale genomic sequencing programs required scalable computing infrastructure. Application analysis covers translational precision medicine, clinical diagnostics, research, agriculture, and population genomics.

Translational precision medicine accounted for approximately 46% of AI genomics demand during 2024 because genomic profiling significantly improves personalized treatment planning and oncology diagnostics. Clinical diagnostics represented 34% of deployment activity due to increasing genomic sequencing for hereditary diseases and biomarker analysis. Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa, focusing on sequencing infrastructure, healthcare digitization, precision medicine initiatives, and cloud analytics adoption. North America accounted for 44% of global AI genomics implementation during 2024 due to strong research infrastructure and advanced healthcare technology integration.